Trial: Sonesitatug Vedotin in Combination With…

Trial Details

Sponsor: AstraZeneca (industry)

Phase: 3

Start date: Feb. 3, 2026

Planned enrollment: 2130

Trial ID: NCT07431281

More trial details at ClinicalTrials.gov

Show Summary from Sponsor

Investigational Drug AI Analysis

Show for: Rilvegostomig (AZD2936)

Overview

Rilvegostomig (AZD2936) is an investigational bispecific monoclonal antibody from AstraZeneca that targets PD‑1 and TIGIT. It is being studied across multiple tumor types, with ongoing phase 3 programs including first‑line metastatic non‑squamous NSCLC (ARTEMIDE‑Lung03), adjuvant biliary tract cancer after resection (ARTEMIDE‑Biliary01), first‑line advanced hepatocellular carcinoma (ARTEMIDE‑HCC01), and first‑line HER2‑positive, PD‑L1–positive gastric/GEJ cancer (ARTEMIDE‑Gastric01). (cdek.pharmacy.purdue.edu)

Mechanism of action

Bispecific IgG1 engineered to bind PD‑1 and TIGIT on the same T cell, aiming to augment antitumor immunity beyond PD‑1 blockade alone. The Fc region carries triple mutations (L234F/L235E/P331S) to reduce Fc‑mediated effector function. (cdek.pharmacy.purdue.edu)
Constructed on a DuetMab backbone; the TIGIT arm derives from Compugen’s anti‑TIGIT antibody (COM902). (cdek.pharmacy.purdue.edu)
Early clinical and translational work suggests high receptor occupancy on peripheral T cells at clinically relevant doses. (pmc.ncbi.nlm.nih.gov)

Efficacy

NSCLC (ARTEMIDE‑01, Phase I/II)

CPI‑pretreated cohort (dose escalation/expansion; PD‑L1 TPS ≥1%): among 83 patients, confirmed ORR 4.8% (all partial responses); median PFS 2.1 months (95% CI 2.0–4.1); 27‑week DCR 31.3%. Recommended phase 2 dose (RP2D) 750 mg Q3W. (oncologypro.esmo.org)
CPI‑naïve cohorts:
PD‑L1 TPS 1–49%: ORR 29%; median PFS 6.0 months (95% CI 2.7–8.4); median DOR 6.4 months (95% CI 4.2–NC). (onclive.com)
PD‑L1 TPS ≥50%: ORR 61.8% (95% CI 43.6–77.8%); median PFS 10.2 months (95% CI 6.3–NC); median DOR 10.3 months (95% CI 8.2–NC). Data are from the first analysis of ARTEMIDE‑01 CPI‑naïve parts C/D and remain preliminary. (onclive.com)

Ongoing phase 3 studies (no efficacy readouts yet)

NSCLC: ARTEMIDE‑Lung03 compares rilvegostomig + platinum/pemetrexed vs pembrolizumab + platinum/pemetrexed in first‑line PD‑L1–positive metastatic non‑squamous NSCLC (started November 2024; target n≈878). (cdek.pharmacy.purdue.edu)
Biliary tract cancer (adjuvant): ARTEMIDE‑Biliary01 evaluates rilvegostomig + investigator’s‑choice chemotherapy (capecitabine, S‑1, or gemcitabine/cisplatin) vs placebo + chemotherapy; primary endpoint recurrence‑free survival (JCO abstract TPS4199; enrollment began 2024; planned n≈750). (ascopubs.org)
Hepatocellular carcinoma: ARTEMIDE‑HCC01 compares rilvegostomig + bevacizumab with or without tremelimumab vs atezolizumab + bevacizumab in first‑line advanced HCC (registered as NCT06921785; launched 2025; planned n≈1220). (smartpatients.com)
Gastric/GEJ (HER2+, PD‑L1 CPS ≥1): ARTEMIDE‑Gastric01 (phase 3) tests rilvegostomig + fluoropyrimidine + trastuzumab deruxtecan vs trastuzumab + chemotherapy + pembrolizumab (3‑arm design; recruiting). (cdek.pharmacy.purdue.edu)

Safety

CPI‑pretreated NSCLC (ARTEMIDE‑01 parts A/B): treatment‑related AEs in 54.2% (grade ≥3 in 8.4%); no grade 4/5 treatment‑related AEs; discontinuations 3.6%. (oncologypro.esmo.org)
CPI‑naïve NSCLC (ARTEMIDE‑01 parts C/D): grade ≥3 treatment‑related AEs 10.5%; treatment‑related discontinuations 4.2%; no clear safety differences between 750 mg and 1500 mg Q3W. (onclive.com)

Key trials (selection)

Phase I/II first‑in‑human NSCLC: ARTEMIDE‑01 (NCT04995523). (cdek.pharmacy.purdue.edu)
Phase III first‑line NSCLC: ARTEMIDE‑Lung03 (NCT06627647). (cdek.pharmacy.purdue.edu)
Phase III adjuvant BTC: ARTEMIDE‑Biliary01 (NCT06109779). (ascopubs.org)
Phase III first‑line HCC: ARTEMIDE‑HCC01 (NCT06921785). (smartpatients.com)
Phase III first‑line HER2+ gastric/GEJ: ARTEMIDE‑Gastric01 (NCT06764875). (cdek.pharmacy.purdue.edu)

Show for: AZD0901 (Sonesitatug vedotin, CMG901)

Overview

AZD0901 (sonesitatug vedotin; formerly CMG901) is an investigational antibody–drug conjugate (ADC) targeting claudin 18.2 (CLDN18.2), being developed primarily for gastric/gastroesophageal junction (G/GEJ) adenocarcinoma and other CLDN18.2-expressing solid tumors. Early-phase clinical data show antitumor activity with a manageable safety profile in previously treated CLDN18.2-positive G/GEJ cancer, and multiple phase 2 and phase 3 trials are ongoing. (pubmed.ncbi.nlm.nih.gov)

Mechanism of action

Target: CLDN18.2, a tight-junction protein aberrantly exposed in several gastrointestinal cancers. (pubmed.ncbi.nlm.nih.gov)
Construct: Humanized anti‑CLDN18.2 IgG1 linked via a protease‑cleavable linker to monomethyl auristatin E (MMAE; “vedotin”). The ADC mediates direct cytotoxicity after internalization and MMAE release, plus immune effector functions (ADCC/CDC) and a bystander effect. (pubmed.ncbi.nlm.nih.gov)

Efficacy

Phase 1 (KYM901, NCT04805307) in advanced G/GEJ cancer (mostly CLDN18.2-positive; Q3W dosing 2.2–3.0 mg/kg):
Confirmed ORR 28% (95% CI 20–38; 32/113) in the full analysis set; ORR 29% (95% CI 21–39; 32/109) in the efficacy set; recommended phase 2 dose (RP2D) 2.2 mg/kg. Median follow-up 9.0 months. (pubmed.ncbi.nlm.nih.gov)
Earlier ASCO abstract reported, among 93 CLDN18.2-positive patients, confirmed ORR 32.6% and median PFS 4.76 months; 9‑month OS rate 56.4%. Data cutoff July 24, 2023. (ascopubs.org)

Ongoing trials (selected): - CLARITY-PanTumor01 (Phase 2, NCT06219941): AZD0901 monotherapy and combinations in advanced CLDN18.2-expressing tumors (G/GEJ, PDAC); primary endpoints include safety and ORR. Recruitment began December 2023. (ascopubs.org) - GEMINI-Gastric (Master Phase 2, NCT05702229): evaluates novel agents including AZD0901 in combination with chemotherapy/immunotherapy in metastatic gastric cancer. (ascopubs.org) - Randomized Phase 3 (NCT06346392): AZD0901 vs ramucirumab/paclitaxel (or investigator’s taxane) in second-line G/GEJ adenocarcinoma; primary completion estimated April 2026. (cdek.pharmacy.purdue.edu)

Safety

Phase 1 dose-escalation/expansion:
Most common treatment-emergent adverse events (any grade): vomiting, decreased appetite, proteinuria, anemia. Grade ≥3 AEs most frequently included decreased neutrophil count (≈21%), anemia (≈14%), and vomiting (≈10%); one treatment-related death reported. Maximum tolerated dose not reached; RP2D 2.2 mg/kg Q3W. (pubmed.ncbi.nlm.nih.gov)
Earlier ASCO readout listed common AEs: anemia, vomiting, hypoalbuminemia; grade ≥3 neutrophil count decreased 18.6% and anemia 13.3%. (ascopubs.org)

Class-related considerations: As an MMAE-bearing ADC, AZD0901’s toxicity profile aligns with other vedotin ADCs (e.g., myelosuppression, GI AEs), consistent with preclinical findings attributing reversible hematopoietic changes to the payload. (pubmed.ncbi.nlm.nih.gov)

Additional notes

Naming and sponsorship: Originally developed as CMG901 by KYM Biosciences (Keymed/Lepu); globally licensed to and now developed by AstraZeneca (AZD0901; USAN nonproprietary name sonesitatug vedotin). (news.cision.com)
Dosing schedule under study: Intravenous administration every 3 weeks (Q3W). RP2D 2.2 mg/kg in Phase 1. (pubmed.ncbi.nlm.nih.gov)

TrialFetch AI Analysis

Goal: To determine whether adding the Claudin18.2-directed antibody–drug conjugate sonesitatug vedotin to fluoropyrimidine-based therapy, with or without the PD-1/TIGIT bispecific antibody rilvegostomig, improves first-line outcomes versus contemporary standard regimens in CLDN18.2-positive, HER2-negative advanced/metastatic gastroesophageal adenocarcinoma, while characterizing safety and supporting the associated CLDN18.2 and PD-L1 diagnostic testing strategy.

Patients: Adults with previously untreated, unresectable locally advanced or metastatic gastric, gastroesophageal junction, or distal esophageal (distal third) adenocarcinoma that is centrally confirmed CLDN18.2-positive and HER2-negative, ECOG 0–1, with RECIST 1.1-assessable disease and adequate organ function. Patients are assigned to cohorts based on centrally confirmed PD-L1 CPS and clinical ICI eligibility: Cohort 1 includes PD-L1–positive and ICI-eligible patients; Cohort 2 includes PD-L1–negative patients or those considered ICI-ineligible.

Design: Global phase III, multicentre, randomized, active-controlled study with two parallel biomarker-defined cohorts. Randomization compares investigational CLDN18.2-directed approaches against current first-line standards within each cohort, with time-to-event follow-up for up to approximately 5 years.

Treatments: Cohort 1 evaluates sonesitatug vedotin plus capecitabine combined with either rilvegostomig (PD-1/TIGIT bispecific) or nivolumab, and compares these against nivolumab plus oxaliplatin-based chemotherapy (CAPOX or FOLFOX). Cohort 2 evaluates sonesitatug vedotin plus capecitabine and compares it against zolbetuximab plus oxaliplatin-based chemotherapy (CAPOX or FOLFOX), with chemotherapy backbone selected per investigator and region. Sonesitatug vedotin (AZD0901) is a CLDN18.2-targeted ADC delivering the microtubule inhibitor MMAE via a cleavable linker; it is designed to exploit CLDN18.2 expression on tumor cells for internalization and payload-mediated cytotoxicity. In phase 1 CLDN18.2-positive gastric/GEJ cohorts, confirmed ORR has been reported in the ~28–33% range with median duration of response about 8 months, with notable toxicities including nausea/vomiting, cytopenias, and risk of peripheral neuropathy consistent with an MMAE payload. Rilvegostomig (AZD2936) is an Fc-silenced IgG1 bispecific antibody targeting PD-1 and TIGIT to enhance antitumor T-cell activity; early phase data in advanced solid tumors suggest manageable immune-related toxicity and pharmacodynamic receptor occupancy, with modest single-agent activity in heavily pretreated populations. Nivolumab is a PD-1 inhibitor used as part of standard first-line immunochemotherapy in appropriate patients, and zolbetuximab is an anti-CLDN18.2 monoclonal antibody used with fluoropyrimidine/oxaliplatin chemotherapy in CLDN18.2-positive disease.

Outcomes: The primary endpoint is progression-free survival (RECIST 1.1) in both Cohort 1 and Cohort 2. Overall survival is also a primary endpoint in Cohort 1 and a secondary endpoint in Cohort 2, with additional prespecified comparisons in Cohort 1 (including OS and PFS for the sonesitatug vedotin plus nivolumab regimen versus nivolumab-based standard therapy). Key secondary endpoints include objective response rate, duration of response, safety/tolerability (AEs/SAEs), pharmacokinetics (Cmax/Cmin) for sonesitatug vedotin (both cohorts) and rilvegostomig (Cohort 1), and immunogenicity (anti-drug antibodies) for both agents.

Burden on patient: Moderate burden. Treatment involves repeated intravenous infusions (sonesitatug vedotin and, in Cohort 1, rilvegostomig or nivolumab) plus continuous oral capecitabine, with standard-of-care-like imaging for RECIST assessment over long-term follow-up. Additional study-specific requirements include prospective central biomarker testing (CLDN18.2 and PD-L1) that may require submission of archival tissue and could necessitate a new biopsy if adequate material is not available, as well as serial pharmacokinetic and immunogenicity blood sampling for investigational agents (more than routine clinical practice). The ADC payload and combination strategies increase the likelihood of closer clinical monitoring for hematologic toxicity, gastrointestinal adverse events, neuropathy, and immune-related events compared with chemotherapy alone.

Last updated: Feb 2026

Eligibility

Show Criteria

Inclusion Criteria:

* Capable of giving signed informed consent

* Participant must be 18 years or the legal age of consent in the jurisdiction in which the study is taking place, at the time of signing the informed consent.

* Previously untreated histologically documented unresectable, locally advanced, or metastatic gastric, GEJ, or distal esophagus (distal third of the esophagus) adenocarcinoma

* Positive CLDN18.2 expression, as determined prospectively by central IHC testing

* Confirmed PD-L1 CPS status by central IHC testing and ICI eligibility per investigator judgement is required to determine cohort eligibility as described below:

1. Cohort 1: PD-L1 positive as determined by central IHC testing and the participant is deemed ICI eligible per investigator judgement.

2. Cohort 2: PD-L1 negative as determined by central IHC testing OR the participant is ICI ineligible

* ECOG performance status of 0 or 1 with no deterioration to \> 1 over the previous 2 weeks prior to baseline at screening and prior to randomisation.

* Minimum life expectancy of ≥ 12 weeks.

* At least one lesion (measurable and/or non-measurable) that can be accurately assessed by the investigator based on RECIST 1.1.

* Adequate organ and bone marrow function as specified in the protocol

* Body weight ≥ 35 kg.

* Sex and contraceptive requirements

Exclusion Criteria:

* Known HER2-positive status

* Significant or unstable gastric bleeding and/or untreated gastric ulcers.

* Active or history of autoimmune or inflammatory disorders requiring systemic treatment with steroids or other immunosuppressive treatment or assessed by investigator as not appropriate to participate due to undue risk are excluded.

* CNS pathology

* Clinically significant pleural effusions or ascites and/or pleural effusions or ascites that require drainage, peritoneal shunt, or indwelling catheter/drain.

* Require parenteral nutrition support due to gastric or gastrointestinal obstruction.

* Peripheral neuropathy, sensory or motor, ≥ CTCAE Grade 2 at screening.

* Persistent toxicities caused by previous anticancer therapy excluding alopecia, not yet improved to Grade ≤ 1 or baseline.

* Cardiac abnormalities as outlined in the protocol

* Uncontrolled diabetes or diabetic neuropathy within 3 months prior to randomisation.

* Infectious disease including active hepatitis A infection; uncontrolled hepatitis B and/or chronic or active hepatitis B with HBV DNA ≥ 100 IU/mL; Known chronic, active, or uncontrolled hepatitis C; HIV infection that is not well controlled

* Known partial or total DPD enzyme deficiency

Sites (230)

Sort by distance to:

Research Site

Montreal, Quebec, H3A 1A1, Canada

No email / No phone

Status: Recruiting

Research Site

Kaohsiung City, 80756, Taiwan

No email / No phone

Status: Recruiting

Research Site

Taichung, 40447, Taiwan

No email / No phone

Status: Recruiting

Research Site

Westmead, 2145, Australia

No email / No phone

Status: Not yet recruiting

Research Site

Randwick, 2031, Australia

No email / No phone

Status: Not yet recruiting

Research Site

Murdoch, 6150, Australia

No email / No phone

Status: Not yet recruiting

Research Site

Heidelberg, 3084, Australia

No email / No phone

Status: Not yet recruiting

Research Site

Garran, 2605, Australia

No email / No phone

Status: Not yet recruiting

Research Site

Brussels, 1200, Belgium

No email / No phone

Status: Not yet recruiting

Research Site

Leuven, 3000, Belgium

No email / No phone

Status: Not yet recruiting

Research Site

Ghent, 9000, Belgium

No email / No phone

Status: Not yet recruiting

Research Site

Edegem, 2650, Belgium

No email / No phone

Status: Not yet recruiting

Research Site

Salvador, 41.950-610, Brazil

No email / No phone

Status: Not yet recruiting

Research Site

Porto Alegre, 91350200, Brazil

No email / No phone

Status: Not yet recruiting

Research Site

Natal, 59075-740, Brazil

No email / No phone

Status: Not yet recruiting

Research Site

Fortaleza, 60336-045, Brazil

No email / No phone

Status: Not yet recruiting

Research Site

Barretos, 14784-400, Brazil

No email / No phone

Status: Not yet recruiting

Research Site

Vitória, 29043-260, Brazil

No email / No phone

Status: Not yet recruiting

Research Site

São Paulo, 01246-000, Brazil

No email / No phone

Status: Not yet recruiting

Research Site

Santa Maria, 97015-450, Brazil

No email / No phone

Status: Not yet recruiting

Research Site

Edmonton, Alberta, T6G 1Z2, Canada

No email / No phone

Status: Not yet recruiting

Research Site

Vancouver, British Columbia, VSZ 4E6, Canada

No email / No phone

Status: Not yet recruiting

Research Site

Abbotsford, British Columbia, V2S0C2, Canada

No email / No phone

Status: Not yet recruiting

Research Site

Winnipeg, Manitoba, R3E 0V9, Canada

No email / No phone

Status: Not yet recruiting

Research Site

Ottawa, Ontario, K1H 8L6, Canada

No email / No phone

Status: Not yet recruiting

Research Site

Toronto, Ontario, M4N 3M5, Canada

No email / No phone

Status: Not yet recruiting

Research Site

Brampton, Ontario, L6R 3J7, Canada

No email / No phone

Status: Not yet recruiting

Research Site

Toronto, Ontario, M5G 2M9, Canada

No email / No phone

Status: Not yet recruiting

Research Site

Québec, Quebec, G1J 1Z4, Canada

No email / No phone

Status: Not yet recruiting

Research Site

Hohhot, 010020, China

No email / No phone

Status: Not yet recruiting

Research Site

Beijing, 100032, China

No email / No phone

Status: Not yet recruiting

Research Site

Beijing, 100050, China

No email / No phone

Status: Not yet recruiting

Research Site

Beijing, 100142, China

No email / No phone

Status: Not yet recruiting

Research Site

Beijing, 102200, China

No email / No phone

Status: Not yet recruiting

Research Site

Changde, 415000, China

No email / No phone

Status: Not yet recruiting

Research Site

Chengdu, 610041, China

No email / No phone

Status: Not yet recruiting

Research Site

Chongqing, 400016, China

No email / No phone

Status: Not yet recruiting

Research Site

Fuzhou, 350005, China

No email / No phone

Status: Not yet recruiting

Research Site

Fuzhou, 350011, China

No email / No phone

Status: Not yet recruiting

Research Site

Guangzhou, 510655, China

No email / No phone

Status: Not yet recruiting

Research Site

Hangzhou, 310003, China

No email / No phone

Status: Not yet recruiting

Research Site

Hangzhou, 310014, China

No email / No phone

Status: Not yet recruiting

Research Site

Hangzhou, 310020, China

No email / No phone

Status: Not yet recruiting

Research Site

Harbin, 150081, China

No email / No phone

Status: Not yet recruiting

Research Site

Hefei, 230031, China

No email / No phone

Status: Not yet recruiting

Research Site

Jinan, 2501117, China

No email / No phone

Status: Not yet recruiting

Research Site

Kunming, 650118, China

No email / No phone

Status: Not yet recruiting

Research Site

Lanzhou, 730000, China

No email / No phone

Status: Not yet recruiting

Research Site

Linhai, 317000, China

No email / No phone

Status: Not yet recruiting

Research Site

Linyi, 276000, China

No email / No phone

Status: Not yet recruiting

Research Site

Nanchang, 330000, China

No email / No phone

Status: Not yet recruiting

Research Site

Nanchang, 330029, China

No email / No phone

Status: Not yet recruiting

Research Site

Nanjing, 2100008, China

No email / No phone

Status: Not yet recruiting

Research Site

Nanjing, 210029, China

No email / No phone

Status: Not yet recruiting

Research Site

Nanning, 530021, China

No email / No phone

Status: Not yet recruiting

Research Site

Nantong, 226361, China

No email / No phone

Status: Not yet recruiting

Research Site

Shanghai, 200025, China

No email / No phone

Status: Not yet recruiting

Research Site

Shanghai, 200127, China

No email / No phone

Status: Not yet recruiting

Research Site

Shanghai, 20032, China

No email / No phone

Status: Not yet recruiting

Research Site

Shantou, 515041, China

No email / No phone

Status: Not yet recruiting

Research Site

Shenyang, 110016, China

No email / No phone

Status: Not yet recruiting

Research Site

Shenzhen, 518036, China

No email / No phone

Status: Not yet recruiting

Research Site

Tianjin, 300050, China

No email / No phone

Status: Not yet recruiting

Research Site

Wuhan, 430030, China

No email / No phone

Status: Not yet recruiting

Research Site

Wuhan, 430079, China

No email / No phone

Status: Not yet recruiting

Research Site

Xi'an, 710068, China

No email / No phone

Status: Not yet recruiting

Research Site

Xiamen, 361003, China

No email / No phone

Status: Not yet recruiting

Research Site

Xingtai, 054031, China

No email / No phone

Status: Not yet recruiting

Research Site

Xuzhou, 221009, China

No email / No phone

Status: Not yet recruiting

Research Site

Yinchuan, 750004, China

No email / No phone

Status: Not yet recruiting

Research Site

Zhengzhou, 450008, China

No email / No phone

Status: Not yet recruiting

Research Site

Berlin, 13353, Germany

No email / No phone

Status: Not yet recruiting

Research Site

Hamburg, 20249, Germany

No email / No phone

Status: Not yet recruiting

Research Site

Heilbronn, 74078, Germany

No email / No phone

Status: Not yet recruiting

Research Site

Freiburg im Breisgau, 79106, Germany

No email / No phone

Status: Not yet recruiting

Research Site

Frankfurt, 60488, Germany

No email / No phone

Status: Not yet recruiting

Research Site

Essen, 45122, Germany

No email / No phone

Status: Not yet recruiting

Research Site

Bonn, 53127, Germany

No email / No phone

Status: Not yet recruiting

Research Site

Leipzig, 04103, Germany

No email / No phone

Status: Not yet recruiting

Research Site

Mainz, 55131, Germany

No email / No phone

Status: Not yet recruiting

Research Site

Moers, 47441, Germany

No email / No phone

Status: Not yet recruiting

Research Site

München, 81657, Germany

No email / No phone

Status: Not yet recruiting

Research Site

Stuttgart, 70376, Germany

No email / No phone

Status: Not yet recruiting

Research Site

Ulm, 89081, Germany

No email / No phone

Status: Not yet recruiting

Research Site

Augsburg, 86156, Germany

No email / No phone

Status: Not yet recruiting

Research Site

Budapest, 1122, Hungary

No email / No phone

Status: Not yet recruiting

Research Site

Zalaegerszeg, 8900, Hungary

No email / No phone

Status: Not yet recruiting

Research Site

Pécs, 7624, Hungary

No email / No phone

Status: Not yet recruiting

Research Site

Nyíregyháza, 4400, Hungary

No email / No phone

Status: Not yet recruiting

Research Site

Gyula, 5700, Hungary

No email / No phone

Status: Not yet recruiting

Research Site

Győr, 9024, Hungary

No email / No phone

Status: Not yet recruiting

Research Site

Debrecen, 4032, Hungary

No email / No phone

Status: Not yet recruiting

Research Site

Budapest, 1083, Hungary

No email / No phone

Status: Not yet recruiting

Research Site

Vijayawada, 520002, India

No email / No phone

Status: Not yet recruiting

Research Site

New Delhi, 110060, India

No email / No phone

Status: Not yet recruiting

Research Site

New Delhi, 110017, India

No email / No phone

Status: Not yet recruiting

Research Site

Mumbai, 400012, India

No email / No phone

Status: Not yet recruiting

Research Site

Mohali, 160055, India

No email / No phone

Status: Not yet recruiting

Research Site

Hyderabad, 500032, India

No email / No phone

Status: Not yet recruiting

Research Site

Bhubaneshwar, 751019, India

No email / No phone

Status: Not yet recruiting

Research Site

Ahmedabad, 380060, India

No email / No phone

Status: Not yet recruiting

Research Site

Meldola, 47014, Italy

No email / No phone

Status: Not yet recruiting

Research Site

Milan, 20133, Italy

No email / No phone

Status: Not yet recruiting

Research Site

Milan, 20141, Italy

No email / No phone

Status: Not yet recruiting

Research Site

Milan, 20162, Italy

No email / No phone

Status: Not yet recruiting

Research Site

Padua, 35128, Italy

No email / No phone

Status: Not yet recruiting

Research Site

Rozzano, 20089, Italy

No email / No phone

Status: Not yet recruiting

Research Site

Tricase, 73039, Italy

No email / No phone

Status: Not yet recruiting

Research Site

Yokohama, 232-0024, Japan

No email / No phone

Status: Not yet recruiting

Research Site

Hirakata-shi, 573-1191, Japan

No email / No phone

Status: Not yet recruiting

Research Site

Kashiwa, 277-8577, Japan

No email / No phone

Status: Not yet recruiting

Research Site

Kitaadachi-gun, 362-0806, Japan

No email / No phone

Status: Not yet recruiting

Research Site

Kōtoku, 135-8550, Japan

No email / No phone

Status: Not yet recruiting

Research Site

Kurashiki-shi, 710-8602, Japan

No email / No phone

Status: Not yet recruiting

Research Site

Niigata, 951-8566, Japan

No email / No phone

Status: Not yet recruiting

Research Site

Osaka, 541-8567, Japan

No email / No phone

Status: Not yet recruiting

Research Site

Sakai, 590-0197, Japan

No email / No phone

Status: Not yet recruiting

Research Site

Sunto-gun, 411-8777, Japan

No email / No phone

Status: Not yet recruiting

Research Site

Warsaw, 02-034, Poland

No email / No phone

Status: Not yet recruiting

Research Site

Olsztyn, 10-228, Poland

No email / No phone

Status: Not yet recruiting

Research Site

Lublin, 20-080, Poland

No email / No phone

Status: Not yet recruiting

Research Site

Krakow, 31-501, Poland

No email / No phone

Status: Not yet recruiting

Research Site

Koszalin, 75-581, Poland

No email / No phone

Status: Not yet recruiting

Research Site

Gdansk, 80-219, Poland

No email / No phone

Status: Not yet recruiting

Research Site

San Juan, 00921, Puerto Rico

No email / No phone

Status: Not yet recruiting

Research Site

Seoul, 06351, South Korea

No email / No phone

Status: Not yet recruiting

Research Site

Seoul, 05505, South Korea

No email / No phone

Status: Not yet recruiting

Research Site

Seoul, 03722, South Korea

No email / No phone

Status: Not yet recruiting

Research Site

Seoul, 03080, South Korea

No email / No phone

Status: Not yet recruiting

Research Site

Seongnam-si, 13620, South Korea

No email / No phone

Status: Not yet recruiting

Research Site

Hwasun-gun, 58128, South Korea

No email / No phone

Status: Not yet recruiting

Research Site

Daegu, 41404, South Korea

No email / No phone

Status: Not yet recruiting

Research Site

Seoul, 06591, South Korea

No email / No phone

Status: Not yet recruiting

Research Site

Santiago de Compostela, 15706, Spain

No email / No phone

Status: Not yet recruiting

Research Site

Barcelona, 08035, Spain

No email / No phone

Status: Not yet recruiting

Research Site

Barcelona, 8036, Spain

No email / No phone

Status: Not yet recruiting

Research Site

Madrid, 28041, Spain

No email / No phone

Status: Not yet recruiting

Research Site

Pamplona, 31008, Spain

No email / No phone

Status: Not yet recruiting

Research Site

Santander, 39008, Spain

No email / No phone

Status: Not yet recruiting

Research Site

Valencia, 46010, Spain

No email / No phone

Status: Not yet recruiting

Research Site

Taoyuan District, 333, Taiwan

No email / No phone

Status: Not yet recruiting

Research Site

Taipei, 112, Taiwan

No email / No phone

Status: Not yet recruiting

Research Site

Taipei, 10002, Taiwan

No email / No phone

Status: Not yet recruiting

Research Site

Tainan, 704, Taiwan

No email / No phone

Status: Not yet recruiting

Research Site

Taichung, Taiwan

No email / No phone

Status: Not yet recruiting

Research Site

Kaohsiung City, 83301, Taiwan

No email / No phone

Status: Not yet recruiting

Research Site

Muang, 22000, Thailand

No email / No phone

Status: Not yet recruiting

Research Site

Khon Kaen, 40002, Thailand

No email / No phone

Status: Not yet recruiting

Research Site

Hat Yai, 90110, Thailand

No email / No phone

Status: Not yet recruiting

Research Site

Dusit, 10300, Thailand

No email / No phone

Status: Not yet recruiting

Research Site

Bangkok, 10700, Thailand

No email / No phone

Status: Not yet recruiting

Research Site

Bangkok, 10210, Thailand

No email / No phone

Status: Not yet recruiting

Research Site

Muang, 70000, Thailand

No email / No phone

Status: Not yet recruiting

Research Site

Medreseboğazı, 01250, Turkey (Türkiye)

No email / No phone

Status: Not yet recruiting

Research Site

Istanbul, 34854, Turkey (Türkiye)

No email / No phone

Status: Not yet recruiting

Research Site

Istanbul, 34098, Turkey (Türkiye)

No email / No phone

Status: Not yet recruiting

Research Site

Antalya, 07100, Turkey (Türkiye)

No email / No phone

Status: Not yet recruiting

Research Site

Ankara, 06530, Turkey (Türkiye)

No email / No phone

Status: Not yet recruiting

Research Site

Şahinbey, 27310, Turkey (Türkiye)

No email / No phone

Status: Not yet recruiting

Research Site

Dundee, DD1 9SY, United Kingdom

No email / No phone

Status: Not yet recruiting

Research Site

Oxford, OX3 7LE, United Kingdom

No email / No phone

Status: Not yet recruiting

Research Site

Cambridge, CB2 0QQ, United Kingdom

No email / No phone

Status: Not yet recruiting

Research Site

Manchester, M20 4BX, United Kingdom

No email / No phone

Status: Not yet recruiting

Research Site

London, EC1A 7BE, United Kingdom

No email / No phone

Status: Not yet recruiting

Research Site

Leeds, LS9 7TF, United Kingdom

No email / No phone

Status: Not yet recruiting

Research Site

Phoenix, Arizona, 85054, United States

No email / No phone

Status: Not yet recruiting

Research Site

Walnut Creek, California, 94598, United States

No email / No phone

Status: Not yet recruiting

Research Site

Duarte, California, 91010, United States

No email / No phone

Status: Not yet recruiting

Research Site

La Jolla, California, 92093, United States

No email / No phone

Status: Not yet recruiting

Research Site

Orange, California, 92868, United States

No email / No phone

Status: Not yet recruiting

Research Site

Lone Tree, Colorado, 80124, United States

No email / No phone

Status: Not yet recruiting

Research Site

Newark, Delaware, 19713, United States

No email / No phone

Status: Not yet recruiting

Research Site

St. Petersburg, Florida, 33705, United States

No email / No phone

Status: Not yet recruiting

Research Site

West Palm Beach, Florida, 33401, United States

No email / No phone

Status: Not yet recruiting

Research Site

Jacksonville, Florida, 32224, United States

No email / No phone

Status: Not yet recruiting

Research Site

Fort Myers, Florida, 33901, United States

No email / No phone

Status: Not yet recruiting

Research Site

Atlanta, Georgia, 30309, United States

No email / No phone

Status: Not yet recruiting

Research Site

Atlanta, Georgia, 30322, United States

No email / No phone

Status: Not yet recruiting

Research Site

Chicago, Illinois, 60637, United States

No email / No phone

Status: Not yet recruiting

Research Site

Niles, Illinois, 60714, United States

No email / No phone

Status: Not yet recruiting

Research Site

Lexington, Kentucky, 40536, United States

No email / No phone

Status: Not yet recruiting

Research Site

Louisville, Kentucky, 40207, United States

No email / No phone

Status: Not yet recruiting

Research Site

Boston, Massachusetts, 02114, United States

No email / No phone

Status: Not yet recruiting

Research Site

Grand Rapids, Michigan, 49503, United States

No email / No phone

Status: Not yet recruiting

Research Site

Burnsville, Minnesota, 55337, United States

No email / No phone

Status: Not yet recruiting

Research Site

Rochester, Minnesota, 55905, United States

No email / No phone

Status: Not yet recruiting

Research Site

Kansas City, Missouri, 64132, United States

No email / No phone

Status: Not yet recruiting

Research Site

St Louis, Missouri, 63110, United States

No email / No phone

Status: Not yet recruiting

Research Site

Hackensack, New Jersey, 07601, United States

No email / No phone

Status: Not yet recruiting

Research Site

East Brunswick, New Jersey, 08816, United States

No email / No phone

Status: Not yet recruiting

Research Site

Summit, New Jersey, 07901, United States

No email / No phone

Status: Not yet recruiting

Research Site

The Bronx, New York, 10461, United States

No email / No phone

Status: Not yet recruiting

Research Site

New York, New York, 10029, United States

No email / No phone

Status: Not yet recruiting

Research Site

New York, New York, 10032, United States

No email / No phone

Status: Not yet recruiting

Research Site

New York, New York, 10065, United States

No email / No phone

Status: Not yet recruiting

Research Site

The Bronx, New York, 10468, United States

No email / No phone

Status: Not yet recruiting

Research Site

Winston-Salem, North Carolina, 27103, United States

No email / No phone

Status: Not yet recruiting

Research Site

Columbus, Ohio, 43221, United States

No email / No phone

Status: Not yet recruiting

Research Site

Portland, Oregon, 97239, United States

No email / No phone

Status: Not yet recruiting

Research Site

Portland, Oregon, 97213, United States

No email / No phone

Status: Not yet recruiting

Research Site

Wilkes-Barre, Pennsylvania, 18711, United States

No email / No phone

Status: Not yet recruiting

Research Site

Hershey, Pennsylvania, 17033, United States

No email / No phone

Status: Not yet recruiting

Research Site

Philadelphia, Pennsylvania, 19104, United States

No email / No phone

Status: Not yet recruiting

Research Site

Pittsburgh, Pennsylvania, 15232, United States

No email / No phone

Status: Not yet recruiting

Research Site

Pittsburgh, Pennsylvania, 15240, United States

No email / No phone

Status: Not yet recruiting

Research Site

Sioux Falls, South Dakota, 57105, United States

No email / No phone

Status: Not yet recruiting

Research Site

Memphis, Tennessee, 38104, United States

No email / No phone

Status: Not yet recruiting

Research Site

Nashville, Tennessee, 37203, United States

No email / No phone

Status: Not yet recruiting

Research Site

Dallas, Texas, 75246, United States

No email / No phone

Status: Not yet recruiting

Research Site

Sherman, Texas, 75090, United States

No email / No phone

Status: Not yet recruiting

Research Site

Blacksburg, Virginia, 24060, United States

No email / No phone

Status: Not yet recruiting

Research Site

Fairfax, Virginia, 22031, United States

No email / No phone

Status: Not yet recruiting

Research Site

Richmond, Virginia, 23219, United States

No email / No phone

Status: Not yet recruiting

Research Site

Fort Belvoir, Virginia, 22060, United States

No email / No phone

Status: Not yet recruiting

Research Site

Seattle, Washington, 98104, United States

No email / No phone

Status: Not yet recruiting

Research Site

Charleston, West Virginia, 25315, United States

No email / No phone

Status: Not yet recruiting

Research Site

Linz, 4010, Austria

No email / No phone

Status: Withdrawn

Research Site

Wiener Neustadt, 2700, Austria

No email / No phone

Status: Withdrawn

Research Site

Vienna, 1090, Austria

No email / No phone

Status: Withdrawn

Research Site

Rankweil, 6830, Austria

No email / No phone

Status: Withdrawn

Research Site

Heidelberg, 69120, Germany

No email / No phone

Status: Withdrawn

Research Site

Mannheim, 68167, Germany

No email / No phone

Status: Withdrawn

Research Site

Varanasi, 221005, India

No email / No phone

Status: Withdrawn

Research Site

New Haven, Connecticut, 06510, United States

No email / No phone

Status: Withdrawn

Research Site

Washington D.C., District of Columbia, 20007, United States

No email / No phone

Status: Withdrawn

Research Site

Atlanta, Georgia, 30342, United States

No email / No phone

Status: Withdrawn

Research Site

White Plains, New York, 10601, United States

No email / No phone

Status: Withdrawn

Research Site

Cleveland, Ohio, 44195, United States

No email / No phone

Status: Withdrawn

Research Site

Falls Church, Virginia, 22042, United States

No email / No phone

Status: Withdrawn

Research Site

Darlinghurst, 2010, Australia

No email / No phone

Status: SUSPENDED

A Phase III, Multicentre, Randomised Controlled Study of Sonesitatug Vedotin in Combination With Capecitabine With or Without Rilvegostomig in First-Line Claudin18.2-Positive, HER2-Negative, Advanced/Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma (CLARITY-Gastric 02)

Trial Details

Show Summary from Sponsor

More details:

Investigational Drug AI Analysis

Show for: Rilvegostomig (AZD2936)

Overview

Mechanism of action

Efficacy

Safety

Key trials (selection)

Further reading

Show for: AZD0901 (Sonesitatug vedotin, CMG901)

Overview

Mechanism of action

Efficacy

Safety

Additional notes

Further reading

TrialFetch AI Analysis

Eligibility

Show Criteria

Sites (230)

Research Site

Research Site

Research Site

Research Site

Research Site

Research Site

Research Site

Research Site

Research Site

Research Site

Research Site

Research Site

Research Site

Research Site

Research Site

Research Site

Research Site

Research Site

Research Site

Research Site

Research Site

Research Site

Research Site

Research Site

Research Site

Research Site

Research Site

Research Site

Research Site

Research Site

Research Site

Research Site

Research Site

Research Site

Research Site

Research Site

Research Site

Research Site

Research Site

Research Site

Research Site

Research Site

Research Site

Research Site

Research Site

Research Site

Research Site

Research Site

Research Site

Research Site

Research Site

Research Site

Research Site

Research Site

Research Site

Research Site

Research Site